Oncology Powerhouse | AstraZeneca's strong oncology portfolio drives growth, with flagship drugs like Imfinzi showing impressive revenue increases despite market challenges |
Pipeline Potential | Explore AstraZeneca's diverse pipeline, including promising treatments in hematologic malignancies and the highly anticipated AVANZAR trial results |
Strategic Growth | Delve into AstraZeneca's strategic acquisitions and partnerships, enhancing its portfolio and pipeline across multiple therapeutic areas |
Market Outlook | Analysts project positive growth, with price targets ranging from $85 to $89, reflecting confidence in AstraZeneca's financial health and market position |
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipAZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 24.0x | −0.4x | |
PEG Ratio | 0.00 | 0.33 | 0.00 | |
Price/Book | 0.0x | 4.3x | 2.6x | |
Price / LTM Sales | 0.0x | 4.3x | 2.9x | |
Upside (Analyst Target) | 0.0% | 12.6% | 56.8% | |
Fair Value Upside | Unlock | 10.6% | 8.9% | Unlock |